P731 Stock Overview
Operates as a pharmaceutical company in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.53 |
| 52 Week High | CA$2.08 |
| 52 Week Low | CA$0.94 |
| Beta | 1.96 |
| 11 Month Change | -10.00% |
| 3 Month Change | 8.51% |
| 1 Year Change | 8.51% |
| 33 Year Change | -38.31% |
| 5 Year Change | -39.76% |
| Change since IPO | -46.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| P731 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -1.8% | -1.8% |
| 1Y | 8.5% | -12.8% | 13.6% |
Return vs Industry: P731 exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: P731 underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| P731 volatility | |
|---|---|
| P731 Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P731's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: P731's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 82 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| P731 fundamental statistics | |
|---|---|
| Market cap | €39.62m |
| Earnings (TTM) | €1.00m |
| Revenue (TTM) | €100.01m |
35.9x
P/E Ratio0.4x
P/S RatioIs P731 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P731 income statement (TTM) | |
|---|---|
| Revenue | US$108.78m |
| Cost of Revenue | US$46.15m |
| Gross Profit | US$62.63m |
| Other Expenses | US$61.54m |
| Earnings | US$1.09m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | 0.044 |
| Gross Margin | 57.57% |
| Net Profit Margin | 1.00% |
| Debt/Equity Ratio | 142.2% |
How did P731 perform over the long term?
See historical performance and comparison